Celldex Offers Safety Profile, Immuno Response Data from Phase 1/2 Study of Varlilumab, Nivolumab at AACR Meeting
April 18, 2016 at 09:02 AM EDT
Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today new safety and immune response data from the Phase 1 portion of a Phase 1/2 ...